মূল্য
দামগুলো আনুমানিক MRP এবং ফার্মেসিভেদে ভিন্ন হতে পারে। সর্বশেষ নথিভুক্ত দামের সাথে তুলনা করে ট্রেন্ড দেখানো হয়।
সব দামের পরিবর্তন →Panzest 25000
Rx300 mg • ক্যাপসুল (এন্টেরিক কোটেড)
ইঙ্গিত ও ব্যবহার
Panzest 25000 is indicated for the treatment of- Exocrine pancreatic insufficiency due to cystic fibrosis Chronic pancreatitis Pancreatectomy or other conditions
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
Infants (up to 12 months): Infants may be given 2,000 to 4,000 lipase units per 120 mL of formula or per breast-feeding. Do not mix pancreatin capsule contents directly into formula or breast milk prior to administration.Children older than 12 months and younger than 4 years: Enzyme dosing should begin with 1,000 lipase units/kg of body weight per meal for children less than age 4 years to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day.Children 4 years and older and adults: Enzyme dosing should begin with 500 lipase units/kg of body weight per meal for those older than age 4 years to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day.Administration: Pancreatin is not interchangeable with any other pancrelipase product. Pancreatin should be swallowed whole. For infants or patients unable to swallow intact capsules, the contents may be administered without crushing or chewing, followed by fluid to ensure complete ingestion.
পার্শ্বপ্রতিক্রিয়া
The most serious adverse reactions reported with different pancreatic enzyme products of the same active ingredient (pancrelipase) include fibrosing colonopathy, hyperuricemia and allergic reactions.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Fibrosing colonopathy: Fibrosing colonopathy has been reported following treatment with different pancreatic enzyme products.Fibrosing colonopathy is a rare, serious adverse reaction initially described in association with high-dose pancreatic enzyme use, usually over a prolonged period of time and most commonly reported in pediatric patients with cystic fibrosis.Potential for Irritation to oral mucosa: Panzest 25000 should not be crushed or chewed or mixed in foods having a pH greater than 4. These actions can disrupt the protective enteric coating resulting in early release of enzymes, irritation of oral mucosa, and/or loss or enzyme activity.Potential for risk of hyperuricemiaPotential viral exposure from the product sourceAllergic reaction